– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy ...

PURCHASE, N.Y., July 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today reported that ...

NASA is looking for far-out ideas. NASA’s Innovative Advanced Concepts (NIAC) Program is seeking Phase II proposals for continuation of promising studies selected during the first phase of the ...

Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability ...

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median ...

The Organisation for Joint Armament Cooperation (OCCAR) and MBDA announced on 15 May that they signed a European Defence Fund (EDF) grant agreement and a linked procurement contract to launch the ...

X6 will initially target oil and gas missions and will also be perfectly suited for Search and Rescue, VIP and other applications. Major marketing, architecture and design choices for the twin-engine ...

Appendix 80HQTR23NOA01-23NIAC_A2 seeks NIAC Phase II awards that will continue the exploration and development of revolutionary advanced concepts started through a NIAC Phase I award. While the Phase ...

Phase IIa clinical trial evaluated Aurase Wound Gel in patients with venous leg ulcers Former Smith+Nephew CMO, Andy Weymann joins as Chairman to support progression of further Phase II clinical ...

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced ...